BioRestorative Therapies (FRA:9OF) ROCE % : -104.34% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioRestorative Therapies's annualized ROCE % for the quarter that ended in Dec. 2023 was -104.34%.

BioRestorative Therapies ROCE % Historical Data

The historical data trend for BioRestorative Therapies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies ROCE % Chart

BioRestorative Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-209.16

-102.79

-108.07

BioRestorative Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-106.69	-155.27	-94.95	-96.03	-104.34

BioRestorative Therapies ROCE % Calculation

BioRestorative Therapies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-13.881	/	( ( (15.515 - 0.415)	+	(11.565 - 0.975) )	/ 2 )
	=	-13.881	/	( (15.1	+	10.59)	/ 2 )
	=	-13.881	/	12.845
	=	-108.07 %

BioRestorative Therapies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-11.816	/	( ( (12.932 - 0.874)	+	(11.565 - 0.975) )	/ 2 )
	=	-11.816	/	( ( 12.058	+	10.59 )	/ 2 )
	=	-11.816	/	11.324
	=	-104.34 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

BioRestorative Therapies (FRA:9OF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioRestorative Therapies ROCE % Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies (FRA:9OF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BRTX:USA

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies (FRA:9OF) Headlines

No Headlines